Form 8-K - Current report:
SEC Accession No. 0001558370-24-014866
Filing Date
2024-11-07
Accepted
2024-11-07 16:11:24
Documents
16
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nxtc-20241107x8k.htm   iXBRL 8-K 49631
2 EX-99.1 nxtc-20241107xex99d1.htm EX-99.1 116451
3 GRAPHIC nxtc-20241107xex99d1001.jpg GRAPHIC 6578
  Complete submission text file 0001558370-24-014866.txt   318421

Data Files

Seq Description Document Type Size
4 EX-101.SCH nxtc-20241107.xsd EX-101.SCH 4061
5 EX-101.DEF nxtc-20241107_def.xml EX-101.DEF 2851
6 EX-101.LAB nxtc-20241107_lab.xml EX-101.LAB 17907
7 EX-101.PRE nxtc-20241107_pre.xml EX-101.PRE 11817
18 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20241107x8k_htm.xml XML 5032
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38905 | Film No.: 241435777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)